cytochalasin h

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	6434468
MeSH ID	M0107255

Synonyms (10)

Synonym
cytochalasin h
53760-19-3
cytochalasin-h
21-acetoxy-7,18-dihydroxy-16,18-dimethyl-10-phenyl-(11)cytochalasa-6(12),13,19-triene-1-one
(11)cytochalasa-6(12),13,19-trien-1-one, 21-(acetyloxy)-7,18-dihydroxy-16,18-dimethyl-10-phenyl-, (7s,13e,16s,18s,19e,21r)-
nsc 305222
kodocytochalasin-1
paspalin p i
HB3862
DTXSID801017589

Research Excerpts

Effects

Excerpt	Reference	Relevance
"Cytochalasin H (CH) has been shown to inhibit the reaggregation of dissociated cells of a fresh water sponge. "	( Inhibitory effect of cytochalasin H on cell reaggregation of the fresh water sponge, Ephydatia meyeni Carter. Ghaskadbi, S; Mulherkar, L, 1982)	2.03

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	3 (30.00)	18.7374
1990's	1 (10.00)	18.2507
2000's	2 (20.00)	29.6817
2010's	4 (40.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	20.06 (24.57)
Research Supply Index	2.56 (2.92)
Research Growth Index	4.99 (4.65)
Search Engine Demand Index	15.26 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (20.06)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	12 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	1.96	1	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
adenosine diphosphate Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.	2	1	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
glucosamine D-glucosamine : An amino sugar whose structure comprises D-glucose having an amino substituent at position 2.. 2-amino-2-deoxy-D-glucopyranose : A D-glucosamine whose structure comprises D-glucopyranose having an amino substituent at position 2.	1.96	1	D-glucosamine	Escherichia coli metabolite; geroprotector; mouse metabolite
sesquiterpenes [no description available]	2.1	1
cytochalasin b Cytochalasin B: A cytotoxic member of the CYTOCHALASINS.. cytochalasin B : An organic heterotricyclic compound, that is a mycotoxin which is cell permeable an an inhibitor of cytoplasmic division by blocking the formation of contractile microfilaments.	1.96	1	cytochalasin; lactam; lactone; organic heterotricyclic compound	actin polymerisation inhibitor; metabolite; mycotoxin; platelet aggregation inhibitor
alternariol alternariol: structure. alternariol : A benzochromenone that is 6H-benzo[c]chromen-6-one which is substituted by a methyl group at position 1 and by hydroxy groups at positions 3, 7, and 9. It is the most important mycotoxin produced by the black mould Alternaria species, which are the most common mycoflora infecting small grain cereals worldwide.	2.1	1	benzochromenone; phenols	EC 3.1.1.8 (cholinesterase) inhibitor; metabolite; mycotoxin
alternariol monomethyl ether djalonensone : A benzochromenone that is alternariol in which the hydroxy group at position 9 has been converted into the corresponding methyl ether. A natural product found in Chaetomium globosum as well as being one of the two most important compounds belonging to the group of Altenaria mycotoxins.	2.1	1	aromatic ether; benzochromenone	antifungal agent; fungal metabolite; mycotoxin
18-dehydroxycytochalasin h 18-dehydroxycytochalasin H: structure given in first source; an inhibitor of HIV-1 protease; isolated from a bark-inhabiting Ascomycete, Hypoxylon fragiforme	1.98	1
deacetylcytochalasin h cytochalasin J: cytochalasin J treatment significantly alters mitotic spindle microtubule organization and kinetochore structure in PtK1 cell	2.1	1
concanavalin a Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.	1.96	1

Condition	Relationship Strength	Studies
Cancer of Lung [description not available]	2.17	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.17	1
Angiogenesis, Pathologic [description not available]	2.51	2
Breast Cancer [description not available]	2.05	1
Cancer of Ovary [description not available]	2.05	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.05	1
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.05	1
Acrania [description not available]	1.96	1
Neural Tube Defects Congenital malformations of the central nervous system and adjacent structures related to defective neural tube closure during the first trimester of pregnancy generally occurring between days 18-29 of gestation. Ectodermal and mesodermal malformations (mainly involving the skull and vertebrae) may occur as a result of defects of neural tube closure. (From Joynt, Clinical Neurology, 1992, Ch55, pp31-41)	1.96	1

chemdatabank.com